The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: Rationale and a summary of the available evidence from phase 3 clinical trials

American Heart Journal

Volumn 169, Issue 3, 2015, Pages 315-322

  Krishnamoorthy, Arun ^a,b   Sherwood, Matthew W ^a,b   Lopes, Renato D ^a,b   Becker, Richard C ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR ACCIDENT; DRUG METABOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONALIZED NORMAL RATIO; KIDNEY FUNCTION; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 84964282769     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.12.008     Document Type: Review

References (37)

1. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
2. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
3. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
4. F. Dentali, N. Riva, and M. Crowther Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature Circulation 126 20 2012 2381 2391
5. J.P. Piccini, T.W. Wallace, and M.R. Patel Stroke prevention in atrial fibrillation Cardiovasc Drugs Ther 25 6 2011 561 570
6. P. Harper, L. Young, and E. Merriman Bleeding risk with dabigatran in the frail elderly N Engl J Med 366 9 2012 864 866
7. M. Levi, E. Eerenberg, and P.W. Kamphuisen Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents J Thromb Haemost 9 9 2011 1705 1712
8. R.W. Harrison, T.L. Ortel, and R.C. Becker To bridge or not to bridge: These are the questions J Thromb Thrombolysis 34 1 2012 31 35
9. L.E. Skolarus, L.B. Morgenstern, and J.B. Froehlich Guideline-discordant periprocedural interruptions in warfarin therapy Circ Cardiovasc Qual Outcomes 4 2 2011 206 210
10. J.S. Healey, J. Eikelboom, and J. Douketis Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial Circulation 126 3 2012 343 348
11. M.W. Sherwood, J.D. Douketis, and M.R. Patel Outcomes of Temporary Interruption of Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF Circulation 129 18 2014 1850 1859
12. D.A. Garcia, J.H. Alexander, and L. Wallentin Management and clinical outcomes in patients treated with apixaban and warfarin undergoing procedures Blood 124 25 2014 3692 3698
13. I. Ahrens, G.Y. Lip, and K. Peter New oral anticoagulant drugs in cardiovascular disease Thromb Haemost 104 1 2010 49 60
14. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 5 2008 285 295
15. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 6 2010 1116 1127
16. D. Kubitza, M. Becka, and A. Roth Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 10 2008 2757 2765
17. D. Kubitza, M. Becka, and G. Wensing Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 12 2005 873 880
18. N. Raghavan, C.E. Frost, and Z. Yu Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 1 2009 74 81
19. H. Heidbuchel, P. Verhamme, and M. Alings EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary Eur Heart J 34 27 2013 2094 2106
20. M.V. Huisman, G.Y. Lip, and H.C. Diener Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice Thromb Haemost 107 5 2012 838 847
21. E. Lindhoff-Last, M.M. Samama, and T.L. Ortel Assays for measuring rivaroxaban: Their suitability and limitations Ther Drug Monit 32 6 2010 673 679
22. J. van Ryn, L. Baruch, and A. Clemens Interpretation of point-of-care INR results in patients treated with dabigatran Am J Med 125 4 2012 417 420
23. National Kidney F KDOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl. 1 2002 S1 S266
24. P.M. Palevsky, K.D. Liu, and P.D. Brophy KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury Am J Kidney Dis 61 5 2013 649 672
25. C.P. Rowley, M.L. Bernard, and W.W. Brabham Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices Am J Cardiol 111 8 2013 1165 1168
26. A.C. Spyropoulos, and J.D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery Blood 120 15 2012 2954 2962
27. B. Charlton, and R.F. Redberg The trouble with dabigatran BMJ 349 2014 g4681
28. S.J. Connolly, L. Wallentin, and M.D. Ezekowitz The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study Circulation 128 3 2013 237 243
29. J.P. Broderick, J.B. Bonomo, and B.M. Kissela Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence Stroke 42 2011 2509 2514
30. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
31. M.P. Donadini, W. Ageno, and J.D. Douketis Management of bleeding in patients receiving conventional or new anticoagulants: A practical and case-based approach Drugs 72 2012 1965 1975
32. J. Stangier, K. Rathgen, and H. Stahle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
33. S. Glund, J. Stangier, and M. Schmohl A Specfic Antidote for Dabigatran: Immediate, Complete, and Sustained Reversal of Anticoagulation in Healthy Male Volunteers Circulation 128 2013 A17765
34. F. Sciele, J. van Ryn, and K. Canada A specific antidote for dabigatran Blood 121 18 2013 3554 3562
35. S. Vanded Daelen, M. Peetermans, and T. Vanassche Monitoring and reversal strategies for new oral anticoagulants Expert Rev Cardiovasc Ther 13 1 2015 95 103
36. S. Schulman, and A. Majeed A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery Drug Saf 34 6 2011 449 463
37. Investigators TBS Bridging anticoagulation: Is it needed when warfarin is interrupted around the time of a surgery or procedure? Circulation 125 12 2012 e496 e498